Necrotizing Enterocolitis Market to Reach $6.94 Billion by 2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Necrotizing Enterocolitis Market Between 2026 And 2030?

The necrotizing enterocolitis market has experienced substantial expansion in recent years. It is projected to increase from $5.14 billion in 2025 to $5.47 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.4%. This historical growth can be linked to factors such as a high rate of premature births, insufficient neonatal care facilities, the prevalent use of broad-spectrum antibiotics, challenges in early diagnosis within low-resource regions, and the initial stages of parenteral nutrition development.

The market for necrotizing enterocolitis is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach $6.95 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.1%. Key drivers for this growth during the projected period include increased investment in neonatal intensive care units, progress in regenerative and stem cell therapies, heightened awareness regarding early nec detection, broader implementation of precision nutrition therapies, and the expansion of innovations in neonatal imaging. Significant trends expected during this forecast span encompass the greater adoption of probiotics and prebiotics for nec prevention, an intensified emphasis on early diagnosis and screening for premature infants, the wider use of individualized tpn solutions, the spread of minimally invasive surgical options, and ongoing improvements in neonatal critical care and monitoring.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22068&type=smp

Which Drivers Are Supporting The Necrotizing Enterocolitis Market Growth?

The future expansion of the necrotizing enterocolitis market is anticipated to be driven by the rising incidence of premature births. Premature births, also known as preterm births, are defined as the birth of an infant prior to 37 weeks of gestation, in contrast to the standard 40-week gestational period. The growing number of premature births stems from maternal health issues such as high blood pressure, diabetes, and infections, which elevate the risk of preterm labor. Additionally, lifestyle elements like smoking, drug consumption, and inadequate nutrition also contribute to a greater probability of premature deliveries. An increase in premature births results in a higher occurrence of necrotizing enterocolitis (NEC) because premature infants possess underdeveloped gastrointestinal systems, making them more vulnerable to inflammation and infection. As an illustration, data from January 2024 by the Centers for Disease Control and Prevention, a US government body, indicates that premature births constitute 8.67% of all annual births in the United States. Consequently, the escalating instances of premature births are fueling the expansion of the necrotizing enterocolitis market.

Which Segment Classifications Are Used In The Necrotizing Enterocolitis Market Segment Analysis?

The necrotizing enterocolitis market covered in this report is segmented –

1) By Treatment: Total Parenteral Nutrition (TPN), Gastrointestinal Decompression, Antimicrobial Therapy, Antifungal Treatment, Paracentesis, Other Treatments

2) By Diagnosis: Laboratory Tests, Imaging Techniques

3) By Stage: Stage I (Suspected Necrotizing Enterocolitis), Stage II (Definite Necrotizing Enterocolitis), Stage III (Advanced Necrotizing Enterocolitis)

4) By End-User: Hospitals, Neonatal Intensive Care Units (NICUs), Specialty Clinics

Subsegments:

1) By Total Parenteral Nutrition (TPN): Standard TPN Formulations, Customized Or Individualized TPN Solutions, Lipid Emulsions For TPN, Protein And Amino Acid Supplements In TPN, Micronutrient And Electrolyte-Enhanced TPN

2) By Gastrointestinal Decompression: Nasogastric Tube (NG Tube) Decompression, Orogastric Tube Decompression, Surgical Gastrostomy For Decompression, Non-Surgical Decompression Techniques

3) By Antimicrobial Therapy: Broad-Spectrum Antibiotics, Gram-Positive Coverage Antibiotics, Gram-Negative Coverage Antibiotics, Combination Antibiotic Therapy, Prophylactic Antibiotic Strategies For High-Risk Neonates

4) By Antifungal Treatment: Systemic Antifungal Therapy, Prophylactic Antifungal Therapy For Preterm Infants, Combination Antifungal And Antibiotic Therapy For Severe NEC

5) By Paracentesis: Diagnostic Paracentesis, Therapeutic Paracentesis, Guided Paracentesis using Ultrasound Or Radiological Techniques

6) By Other Treatments: Probiotics And Prebiotics for NEC Prevention, Surgical Interventions, Stem Cell Therapy And Regenerative Medicine Approaches, Immunomodulatory Therapies, Supportive Care

Which Trends Are Expected To Impact The Necrotizing Enterocolitis Market?

Leading companies within the necrotizing enterocolitis market are concentrating on developing innovative product solutions, such as cell-free sterile biologic solutions, to address the vital unmet need for effective therapies and improve outcomes for premature infants. A cell-free sterile biologic solution is a purified, sterile liquid composed of bioactive molecules like proteins, growth factors, and cytokines derived from cultured cells, but without any intact cells, specifically designed to foster healing and reduce inflammation. For instance, in December 2023, Noveome Biotherapeutics, Inc., a US-based biopharmaceutical company, received authorization from the U.S. Food and Drug Administration (FDA) to proceed with its Phase 1-2 clinical trial for ST266, a novel biologic targeting necrotizing enterocolitis (NEC) in premature infants. This signifies a major milestone, as ST266 is projected to be the first significant therapeutic advancement for NEC in over 30 years, thereby addressing a critical medical necessity given the disease’s high morbidity and mortality rates among vulnerable populations.

Which Firms Are Contributing To The Necrotizing Enterocolitis Market Ecosystem?

Major companies operating in the necrotizing enterocolitis market are Abbott Laboratories, Astellas Pharma Inc., Mayo Foundation for Medical Education and Research, Cleveland Clinic, Boston Children’s Hospital, Hollister Incorporated, UPMC Children’s Hospital of Pittsburgh, Prolacta Bioscience Inc., Evolve BioSystems, Sigma-Tau Pharmaceuticals, Mead Johnson & Company LLC, Liminal BioSciences Inc., Noveome Biotherapeutics Inc., Infant Bacterial Therapeutics, Prometic Life Sciences Inc., Nexilico, Siolta Therapeutics, ProThera Biologics Inc., Plakous Therapeutics Inc., Chosen Diagnostics Inc.

Get The Full Necrotizing Enterocolitis Market Report:

https://www.thebusinessresearchcompany.com/report/necrotizing-enterocolitis-global-market-report

Which Region Is The Top Contributor To The Necrotizing Enterocolitis Market By Share?

North America was the largest region in the necrotizing enterocolitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the necrotizing enterocolitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Necrotizing Enterocolitis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/necrotizing-enterocolitis-global-market-report

Browse Through More Reports Similar to the Global Necrotizing Enterocolitis Market 2026, By The Business Research Company

Lipid Market Report 2026

https://www.thebusinessresearchcompany.com/report/lipid-global-market-report

Antidiabetics Market Report

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Lip Care Product Market Report

https://www.thebusinessresearchcompany.com/report/lip-care-product-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795